The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Cancer Drug based on CAR-T Market Research Report 2025
Synopsis
A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called chimeric antigen receptor T-cell therapy.
The global Cancer Drug based on CAR-T market was valued at US$ 632 million in 2023 and is anticipated to reach US$ 913.9 million by 2030, witnessing a CAGR of 5.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Cancer Drug based on CAR-T, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Drug based on CAR-T.
Report Scope
The Cancer Drug based on CAR-T market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Drug based on CAR-T market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Drug based on CAR-T companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Fosun Kite Biotechnology
Gilead Sciences
Novartis
Bristol-Myers Squibb
Segment by Type
Allogeneic
Autologous
Segment by Application
Hospital
Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Drug based on CAR-T companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called chimeric antigen receptor T-cell therapy.
The global Cancer Drug based on CAR-T market was valued at US$ 632 million in 2023 and is anticipated to reach US$ 913.9 million by 2030, witnessing a CAGR of 5.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Cancer Drug based on CAR-T, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Drug based on CAR-T.
Report Scope
The Cancer Drug based on CAR-T market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Drug based on CAR-T market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Drug based on CAR-T companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Fosun Kite Biotechnology
Gilead Sciences
Novartis
Bristol-Myers Squibb
Segment by Type
Allogeneic
Autologous
Segment by Application
Hospital
Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Drug based on CAR-T companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer Drug based on CAR-T Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Allogeneic
1.2.3 Autologous
1.3 Market by Application
1.3.1 Global Cancer Drug based on CAR-T Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cancer Drug based on CAR-T Market Perspective (2019-2030)
2.2 Cancer Drug based on CAR-T Growth Trends by Region
2.2.1 Global Cancer Drug based on CAR-T Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Cancer Drug based on CAR-T Historic Market Size by Region (2019-2024)
2.2.3 Cancer Drug based on CAR-T Forecasted Market Size by Region (2025-2030)
2.3 Cancer Drug based on CAR-T Market Dynamics
2.3.1 Cancer Drug based on CAR-T Industry Trends
2.3.2 Cancer Drug based on CAR-T Market Drivers
2.3.3 Cancer Drug based on CAR-T Market Challenges
2.3.4 Cancer Drug based on CAR-T Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer Drug based on CAR-T Players by Revenue
3.1.1 Global Top Cancer Drug based on CAR-T Players by Revenue (2019-2024)
3.1.2 Global Cancer Drug based on CAR-T Revenue Market Share by Players (2019-2024)
3.2 Global Cancer Drug based on CAR-T Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cancer Drug based on CAR-T Revenue
3.4 Global Cancer Drug based on CAR-T Market Concentration Ratio
3.4.1 Global Cancer Drug based on CAR-T Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Drug based on CAR-T Revenue in 2023
3.5 Cancer Drug based on CAR-T Key Players Head office and Area Served
3.6 Key Players Cancer Drug based on CAR-T Product Solution and Service
3.7 Date of Enter into Cancer Drug based on CAR-T Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Drug based on CAR-T Breakdown Data by Type
4.1 Global Cancer Drug based on CAR-T Historic Market Size by Type (2019-2024)
4.2 Global Cancer Drug based on CAR-T Forecasted Market Size by Type (2025-2030)
5 Cancer Drug based on CAR-T Breakdown Data by Application
5.1 Global Cancer Drug based on CAR-T Historic Market Size by Application (2019-2024)
5.2 Global Cancer Drug based on CAR-T Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Cancer Drug based on CAR-T Market Size (2019-2030)
6.2 North America Cancer Drug based on CAR-T Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Cancer Drug based on CAR-T Market Size by Country (2019-2024)
6.4 North America Cancer Drug based on CAR-T Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cancer Drug based on CAR-T Market Size (2019-2030)
7.2 Europe Cancer Drug based on CAR-T Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Cancer Drug based on CAR-T Market Size by Country (2019-2024)
7.4 Europe Cancer Drug based on CAR-T Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cancer Drug based on CAR-T Market Size (2019-2030)
8.2 Asia-Pacific Cancer Drug based on CAR-T Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Cancer Drug based on CAR-T Market Size by Region (2019-2024)
8.4 Asia-Pacific Cancer Drug based on CAR-T Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cancer Drug based on CAR-T Market Size (2019-2030)
9.2 Latin America Cancer Drug based on CAR-T Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Cancer Drug based on CAR-T Market Size by Country (2019-2024)
9.4 Latin America Cancer Drug based on CAR-T Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer Drug based on CAR-T Market Size (2019-2030)
10.2 Middle East & Africa Cancer Drug based on CAR-T Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Cancer Drug based on CAR-T Market Size by Country (2019-2024)
10.4 Middle East & Africa Cancer Drug based on CAR-T Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Fosun Kite Biotechnology
11.1.1 Fosun Kite Biotechnology Company Detail
11.1.2 Fosun Kite Biotechnology Business Overview
11.1.3 Fosun Kite Biotechnology Cancer Drug based on CAR-T Introduction
11.1.4 Fosun Kite Biotechnology Revenue in Cancer Drug based on CAR-T Business (2019-2024)
11.1.5 Fosun Kite Biotechnology Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Detail
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences Cancer Drug based on CAR-T Introduction
11.2.4 Gilead Sciences Revenue in Cancer Drug based on CAR-T Business (2019-2024)
11.2.5 Gilead Sciences Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Cancer Drug based on CAR-T Introduction
11.3.4 Novartis Revenue in Cancer Drug based on CAR-T Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Cancer Drug based on CAR-T Introduction
11.4.4 Bristol-Myers Squibb Revenue in Cancer Drug based on CAR-T Business (2019-2024)
11.4.5 Bristol-Myers Squibb Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
